Curaleaf Holdings (CURA) Stock Overview
Engages in the retail and wholesale of cannabis products in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CURA Community Fair Values
Create NarrativeSee what 28 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Curaleaf Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$15.31 |
| 52 Week High | CA$20.93 |
| 52 Week Low | CA$3.36 |
| Beta | 1.64 |
| 1 Month Change | 5.22% |
| 3 Month Change | 64.09% |
| 1 Year Change | 343.77% |
| 3 Year Change | 21.51% |
| 5 Year Change | -70.33% |
| Change since IPO | -40.45% |
Recent News & Updates
Narrative Update • Jun 24
CURA: Governance Restructuring And Share Repurchases Will Support Future Earnings Power
Analysts have lifted their price target on Curaleaf Holdings by CA$1, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E based on the latest research. What’s in the News for Curaleaf Holdings Shareholders approved an amendment to Curaleaf Holdings' multiple voting shares held by CEO and Chairman Boris Jordan, removing the automatic conversion trigger that was previously linked to a U.S. listing of the Subordinate Voting Shares.Analysis Article • Jun 18
Curaleaf Holdings (TSX:CURA) Stock Could Be 163% Overvalued After Voting Share Change Proposal
Curaleaf Holdings (TSX:CURA) has put governance in focus after filing a supplement to its management information circular that asks shareholders to amend CEO Boris Jordan's multiple voting shares and extends the proxy cut off. See our latest analysis for Curaleaf Holdings. At a share price of CA$13.43, Curaleaf Holdings has recently eased back, with the 7 day share price return down 7.38% and the 30 day share price return down 4.55%. However, the 90 day share price return of 41.67% and 1 year...Recent updates
Narrative Update • Jun 24
CURA: Governance Restructuring And Share Repurchases Will Support Future Earnings Power
Analysts have lifted their price target on Curaleaf Holdings by CA$1, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E based on the latest research. What’s in the News for Curaleaf Holdings Shareholders approved an amendment to Curaleaf Holdings' multiple voting shares held by CEO and Chairman Boris Jordan, removing the automatic conversion trigger that was previously linked to a U.S. listing of the Subordinate Voting Shares.Analysis Article • Jun 18
Curaleaf Holdings (TSX:CURA) Stock Could Be 163% Overvalued After Voting Share Change Proposal
Curaleaf Holdings (TSX:CURA) has put governance in focus after filing a supplement to its management information circular that asks shareholders to amend CEO Boris Jordan's multiple voting shares and extends the proxy cut off. See our latest analysis for Curaleaf Holdings. At a share price of CA$13.43, Curaleaf Holdings has recently eased back, with the 7 day share price return down 7.38% and the 30 day share price return down 4.55%. However, the 90 day share price return of 41.67% and 1 year...
Narrative Update • Jun 04
CURA: Uplisting Preparations And Reverse Split Will Constrain Future Upside Potential
Analysts have raised their CA$ price target for Curaleaf Holdings by CA$1, reflecting updated views on fair value, the discount rate, revenue growth, profit margins, and future P/E assumptions. What's in the News Curaleaf announced a 1-for-3 reverse stock split of its shares, expected to take effect on or about June 5, 2026, in preparation for a potential uplisting to a major U.S. stock exchange following regulatory developments in the cannabis industry.
Narrative Update • May 21
CURA: Domestic Stabilization And International Expansion Will Support Future Re Rating
Analysts recently raised their Curaleaf Holdings price target by CA$1 to CA$5.50, citing expectations for steadier domestic operations alongside ongoing international growth opportunities. Analyst Commentary Recent research commentary around Curaleaf highlights a mix of optimism about international prospects and a more guarded stance on valuation and execution in the core business.Narrative Update • Apr 30
CURA: Domestic Stabilization And International Expansion Will Drive Future Upside Confidence
Analysts trimmed their Curaleaf Holdings price target to CA$5.50 from CA$6.00, citing a modest Q4 sales beat, signs of stabilization in the domestic business, and ongoing international growth opportunities. Analyst Commentary Bullish analysts trimmed their Curaleaf price target to CA$5.50 from CA$6.00 after the latest Q4 update, but still framed the move within a generally constructive view of the story.Narrative Update • Apr 16
CURA: Domestic Stabilization And International Expansion Will Support Future Earnings Power
Analysts have trimmed their 12 month price target on Curaleaf Holdings to CA$5.50 from CA$6.00, citing a recent slight Q4 sales beat, efforts to stabilize the domestic business, and ongoing international growth opportunities. Analyst Commentary Recent research reflects a more tempered stance on Curaleaf Holdings, with the 12 month price target brought down to CA$5.50 from CA$6.Narrative Update • Apr 02
CURA: Domestic Stabilization Efforts Will Support Bullish Re Rating
Analysts now see Curaleaf's fair value drifting slightly higher, even as the average Street price target edges down from CA$6.00 to CA$5.50. They cite recent sales results and efforts to steady the core business while keeping international growth in focus.Narrative Update • Mar 19
CURA: Domestic Stabilization And International Expansion Will Support Wider Future Moat
Curaleaf Holdings’ consensus analyst price target has shifted from CA$6.00 to CA$5.50 as analysts factor in the recent slight Q4 sales beat, along with views that its domestic operations are stabilizing and international markets continue to offer potential for further expansion. Analyst Commentary Bullish Takeaways Bullish analysts view the slight Q4 sales beat as evidence that Curaleaf can at least meet, and at times exceed, current expectations, which supports the revised CA$5.50 price target as still offering room for execution upside if that trend holds.Narrative Update • Mar 04
CURA: Domestic Stabilization And International Expansion Will Support Future Upside
Analysts have trimmed their price target on Curaleaf Holdings to CA$5.50 from CA$6.00, citing a recent slight Q4 sales beat, efforts to stabilize the domestic business, and ongoing international growth opportunities. Analyst Commentary Bullish analysts trimmed their Curaleaf price target to CA$5.50 from CA$6.00, but are still framing the move as a recalibration rather than a negative call.Narrative Update • Feb 18
CURA: Refinancing And Hemp Exit Will Support Wider Future Moat
Analysts have slightly adjusted their CA$ fair value estimate for Curaleaf Holdings to reflect updated assumptions on revenue growth, profit margins, and future P/E expectations. This has led to a modest change in the implied price target.Narrative Update • Feb 04
CURA: Expanded Retail Footprint And Higher Guidance Will Support Bullish Re Rating
Analysts have trimmed their price target on Curaleaf Holdings to about US$4.37 from roughly US$4.40, reflecting updated views on revenue growth, profit margins, and a lower assumed future P/E multiple. What's in the News Curaleaf opened an adult use store adjacent to its existing medical dispensary at 829 Hogan Rd., Bangor, Maine, bringing its retail footprint to five locations in Maine and 161 locations across the United States (Key Developments).Narrative Update • Jan 21
CURA: Regulatory Shift And Exit From Hemp Will Support Wider Moat
Analysts have made a small upward adjustment to their implied price outlook for Curaleaf Holdings, reflecting slightly higher fair value estimates and a modestly higher future P/E assumption in their models. What's in the News Curaleaf raised its fourth quarter 2025 net revenue guidance excluding discontinued businesses to at least US$330 million.Narrative Update • Jan 07
CURA: Regulatory Shifts Will Widen Moat And Support Destination Brand Position
Analysts have lifted their price target on Curaleaf Holdings to C$5.00 from C$4.81, pointing to regulatory momentum and what they see as a stronger product offering that could help the company reinforce its position with consumers. Analyst Commentary Recent commentary has focused on how regulatory shifts and Curaleaf's product positioning could influence the company’s valuation and execution over time.Narrative Update • Dec 23
CURA: Regulatory Momentum Will Likely Drive A Bullish Re-Rating Ahead
Analysts have raised their price target on Curaleaf Holdings from C$2.65 to C$4.40, citing improving growth and profitability expectations, along with a more favorable regulatory backdrop that could drive a broader sector re rating. Analyst Commentary While the latest forecast revisions highlight improving fundamentals for Curaleaf Holdings, recent Street research also underscores a more nuanced outlook, with some market participants emphasizing residual risks around execution and the regulatory timeline.Analysis Article • Dec 13
Curaleaf Holdings, Inc. (TSE:CURA) Stock Rockets 31% As Investors Are Less Pessimistic Than Expected
Curaleaf Holdings, Inc. ( TSE:CURA ) shares have continued their recent momentum with a 31% gain in the last month...Narrative Update • Dec 09
CURA: Regulatory Shifts Will Drive Stronger Moat And Index Inclusion Tailwinds
Analysts have nudged their price target on Curaleaf Holdings modestly higher, lifting fair value estimates to approximately $4.81 from about $4.75 per share. They cite improving revenue growth expectations and a strengthening competitive moat amid an increasingly favorable regulatory backdrop.Narrative Update • Nov 24
CURA: Upcoming Regulatory Shifts Will Likely Drive Stronger Sector Momentum
Analysts have raised their price target for Curaleaf Holdings from $4.21 to $4.75 per share. They cited improved profit margins, stronger revenue growth projections, and renewed optimism around sector regulatory changes.Narrative Update • Nov 07
CURA: Regulatory Momentum Will Likely Drive Stronger Market Presence This Year
Analysts have raised their price target for Curaleaf Holdings from $4.06 to $4.21. They cite improved revenue growth estimates and the company’s strengthened market position as key factors behind the upward revision.Narrative Update • Oct 24
Regulatory Winds Will Drive New Industry Leadership And Outperformance Opportunities
Analysts have raised their price target for Curaleaf Holdings to C$5, citing expectations that upcoming regulatory changes and the company's strengthened market position could significantly enhance its valuation. Analyst Commentary Analyst coverage on Curaleaf Holdings highlights both notable optimism surrounding the company's trajectory and areas where caution may be warranted.Analysis Article • Oct 12
There's Reason For Concern Over Curaleaf Holdings, Inc.'s (TSE:CURA) Massive 27% Price Jump
Despite an already strong run, Curaleaf Holdings, Inc. ( TSE:CURA ) shares have been powering on, with a gain of 27% in...Narrative Update • Oct 10
Expanding German And Turkish Markets Will Unlock Global Opportunities
Narrative Update: Curaleaf Holdings Analyst Price Target Analysts have raised Curaleaf Holdings' fair value estimate from $3.83 to $4.06, citing increased expectations for regulatory progress and Curaleaf's ongoing brand strength in the cannabis sector. Analyst Commentary Bullish Takeaways Bullish analysts see regulatory progress as a key catalyst that could enhance Curaleaf's valuation in the near term.Narrative Update • Sep 04
Expanding German And Turkish Markets Will Unlock Global Opportunities
Despite steady revenue growth forecasts, Curaleaf Holdings' future P/E multiple has increased markedly, signaling a higher valuation relative to earnings and maintaining the consensus analyst price target at CA$3.83. Valuation Changes Summary of Valuation Changes for Curaleaf Holdings The Consensus Analyst Price Target remained effectively unchanged, at CA$3.83.Analysis Article • Jul 11
Why Investors Shouldn't Be Surprised By Curaleaf Holdings, Inc.'s (TSE:CURA) 41% Share Price Surge
The Curaleaf Holdings, Inc. ( TSE:CURA ) share price has done very well over the last month, posting an excellent gain...
New Narrative • Mar 24
Premium Flower And European Medical Programs Will Create Future Opportunities
Strategic initiatives like the ROOTS program and operational efficiencies aim to enhance margins and strengthen financial health.Analysis Article • Mar 07
The Price Is Right For Curaleaf Holdings, Inc. (TSE:CURA) Even After Diving 30%
To the annoyance of some shareholders, Curaleaf Holdings, Inc. ( TSE:CURA ) shares are down a considerable 30% in the...Analysis Article • Dec 15
Here's Why Curaleaf Holdings (TSE:CURA) Has A Meaningful Debt Burden
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analysis Article • Nov 09
Investors Give Curaleaf Holdings, Inc. (TSE:CURA) Shares A 27% Hiding
To the annoyance of some shareholders, Curaleaf Holdings, Inc. ( TSE:CURA ) shares are down a considerable 27% in the...Analysis Article • Aug 13
Curaleaf Holdings, Inc. (TSE:CURA) Shares Slammed 25% But Getting In Cheap Might Be Difficult Regardless
Unfortunately for some shareholders, the Curaleaf Holdings, Inc. ( TSE:CURA ) share price has dived 25% in the last...Analysis Article • Jul 19
These 4 Measures Indicate That Curaleaf Holdings (TSE:CURA) Is Using Debt Extensively
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analysis Article • Jun 14
Some Confidence Is Lacking In Curaleaf Holdings, Inc. (TSE:CURA) As Shares Slide 27%
Curaleaf Holdings, Inc. ( TSE:CURA ) shares have had a horrible month, losing 27% after a relatively good period...Analysis Article • Jan 19
Subdued Growth No Barrier To Curaleaf Holdings, Inc. (TSE:CURA) With Shares Advancing 25%
The Curaleaf Holdings, Inc. ( TSE:CURA ) share price has done very well over the last month, posting an excellent gain...Analysis Article • Dec 11
Does Curaleaf Holdings (CSE:CURA) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Shareholder Returns
| CURA | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 16.1% | 1.9% | -1.0% |
| 1Y | 343.8% | 51.9% | 28.9% |
Return vs Industry: CURA exceeded the Canadian Pharmaceuticals industry which returned 51.9% over the past year.
Return vs Market: CURA exceeded the Canadian Market which returned 28.9% over the past year.
Price Volatility
| CURA volatility | |
|---|---|
| CURA Average Weekly Movement | 15.1% |
| Pharmaceuticals Industry Average Movement | 10.2% |
| Market Average Movement | 9.7% |
| 10% most volatile stocks in CA Market | 16.6% |
| 10% least volatile stocks in CA Market | 3.7% |
Stable Share Price: CURA's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: CURA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 5,554 | Boris Jordan | www.curaleaf.com |
Curaleaf Holdings, Inc. engages in the retail and wholesale of cannabis products in the United States and internationally. The company operates licensed cultivation; and pharma-grade cannabis processing and manufacturing facilities. It also supplies cannabis on a wholesale basis to Australia, New Zealand, the United Kingdom and various European countries, including Germany, Italy, Poland, the Czech Republic, Switzerland, Sweden and Norway.
Curaleaf Holdings, Inc. Fundamentals Summary
| CURA fundamental statistics | |
|---|---|
| Market cap | CA$3.82b |
| Earnings (TTM) | -CA$160.82m |
| Revenue (TTM) | CA$1.83b |
2.2x
P/S Ratio-25.1x
P/E RatioIs CURA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CURA income statement (TTM) | |
|---|---|
| Revenue | US$1.29b |
| Cost of Revenue | US$653.00m |
| Gross Profit | US$632.75m |
| Other Expenses | US$745.95m |
| Earnings | -US$113.21m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 05, 2026
| Earnings per share (EPS) | -0.43 |
| Gross Margin | 49.21% |
| Net Profit Margin | -8.80% |
| Debt/Equity Ratio | 85.1% |
How did CURA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/30 22:04 |
| End of Day Share Price | 2026/06/30 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Curaleaf Holdings, Inc. is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Russell Stanley | Beacon Securities Limited |